| Sep 24 |
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
|
| Sep 24 |
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
|
| Sep 24 |
Top Midday Gainers
|
| Sep 24 |
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
|
| Sep 24 |
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
|
| Sep 24 |
Wave Life Sciences gains on data for Duchenne therapy
|
| Sep 24 |
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
|
| Sep 23 |
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
|
| Sep 19 |
Wave Life Sciences gains as B. Riley issues buy on RNS editing tech
|
| Sep 9 |
Wave Life Sciences initiated with Overweight at J.P. Morgan
|
